+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 10 Actively Recruiting clinical trials

P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating SYX-5219 in a multi-part, first-in-human Phase 1 study involving healthy volunteers and people with moderate to severe atopic dermatitis AD. The study aims to determine the safety, tolerability, and levels of SYX-5219 in blood and urine when given in different dosing schedules. This includes single ascending doses, multiple ascending doses, and multiple dose administrations in participants with AD. The study has three parts Part 1 involves single ascending doses and a food effect evaluation in healthy volunteers, with doses given once on Day 1 and again after a washout period. Part 2 involves multiple ascending doses given once or twice daily to healthy volunteers over a defined period. Part 3 enrolls participants with AD who receive SYX-5219 or placebo twice daily for up to 42 days. Each part includes randomization and placebo control to compare effects. Participants will undergo safety and exploratory efficacy assessments during and after treatment, including monitoring adverse events up to 10 days after dosing in Part 1, 14 days after the last dose in Part 2, and up to Day 56 in Part 3. Blood and urine samples are collected at multiple timepoints to measure SYX-5219 levels. The study includes follow-up visits to monitor participant health and drug effects for several weeks after treatment ends.

Age: 18Years - 65YearsAll GendersPhase 1
14 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of ENV-294, an oral investigational drug, in adults with moderate-to-severe atopic dermatitis AD. This double-blind, placebo-controlled Phase 2b study compares three different doses of ENV-294 against a placebo over 12 weeks. The study aims to better understand how ENV-294 affects disease severity, symptoms, quality of life, and biological markers in people with chronic AD. Participants will be randomly assigned to one of four groups receiving either one of three doses of ENV-294 or a matching placebo. The treatment is taken once daily by mouth for 12 weeks. Before starting treatment, participants undergo screening to confirm eligibility based on their AD diagnosis, disease severity, and treatment history. During the study, participants complete regular assessments of their eczema severity using standardized scores like the Eczema Area and Severity Index EASI, patient-reported outcomes, safety checks, blood tests for drug levels, and biomarker analysis. Researchers monitor for any adverse events throughout the 12 weeks and for an additional 4 weeks following treatment. The total participation time includes screening, treatment, and follow-up assessments to evaluate both the effects and safety of ENV-294.

Age: 18Years +All GendersPhase 2
9 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness of adding the drug tirzepatide to ongoing ixekizumab therapy in adults with moderate-to-severe plaque psoriasis who are also overweight or obese with at least one weight-related health condition. This Phase 4 study aims to assess how well this combination works in real-world clinical practice over a period of up to 12 months. Participants will continue their prescribed ixekizumab treatment and start taking tirzepatide through subcutaneous injections according to approved guidelines. The study is designed as a single-arm, open-label trial where all participants receive tirzepatide along with ixekizumab. The treatment period covers about one year, during which the response to this combined therapy will be closely observed. Throughout the study, participants will undergo regular assessments to measure improvements in their skin condition and weight. Key outcomes include the percentage achieving minimal impact on quality of life related to dermatology and at least 10% weight loss after 12 months. Additional evaluations at 6 and 12 months will monitor skin involvement, global physician and patient assessments, and weight changes. Safety and tolerability will also be followed during this time.

Age: 18Years +All GendersPhase 4
38 locations
L

Actively Recruiting

This research aims to evaluate the long-term safety and effectiveness of ORKA-001 in adults who have moderate-to-severe plaque psoriasis and previously took part in an Oruka Therapeutics study. It is an open-label extension study where all participants receive the study drug to monitor ongoing treatment effects and safety over an extended period. Participants will receive ORKA-001 as a subcutaneous injection through different dosing schedules once a year high or low dose, twice a year, or no drug until meeting specific response criteria. The treatment period can last up to about 96 weeks, followed by a post-treatment follow-up lasting approximately 48 weeks after the last study visit. During the study, participants will undergo safety monitoring, including checking for adverse events. Effectiveness will be assessed by measuring skin condition improvements using tools like the Psoriasis Area and Severity Index PASI and Investigators Global Assessment IGA. The team will track these results over time to understand how participants maintain their skin improvements and overall treatment tolerance.

Age: 18Years +All GendersPhase 2
39 locations
L

Actively Recruiting

This research evaluates the long-term safety and effectiveness of YCANTH also known as VP-102 or TO-208 in people who have common warts and previously participated in related studies COVE-2 or COVE-3. The study aims to monitor side effects, especially local skin reactions, and to assess how well continued application of YCANTH clears warts over time. Participants with warts will receive up to four additional treatments of YCANTH applied to each wart every 21 days, with the option to pause if skin reactions occur. Clear warts are covered with occlusive tape overnight after treatment. If new warts appear after clearance, treatment resumes. Participants without warts attend observation visits every 42 days. Those with remaining warts after four treatments may discontinue and seek other therapies. Throughout the study, participants will attend visits up to day 378, including treatment and observation periods. Researchers will assess adverse events, vital signs, medication use, and wart clearance at each visit. Treatments involve wart paring if needed before drug application. The study tracks safety and wart reduction until the final visit nearly a year after starting this follow-up phase.

Age: 2Years +All GendersPhase 3
12 locations
R

Actively Recruiting

Researchers are evaluating ORKA-002, a drug administered by subcutaneous injection, in adult participants with moderate-to-severe Hidradenitis Suppurativa HS. This multicenter, randomized, double-blind, placebo-controlled study aims to assess the efficacy, safety, tolerability, and pharmacokinetics of ORKA-002 compared to placebo. The study is sponsored by Oruka Therapeutics, Inc. and involves participants who have had HS symptoms for at least 6 months with lesions in multiple areas and prior inadequate response or intolerance to systemic antibiotics. Participants will be randomly assigned to receive either ORKA-002 or placebo every 4 weeks during a 12-week double-blind induction period through Week 16. After this, all participants will enter an open-label maintenance period where ORKA-002 is given every 12 weeks. The study includes four distinct periods screening, induction double-blind, maintenance open-label, and post-treatment follow-up. During the study, participants will undergo regular assessments including the Hidradenitis Suppurativa Clinical Response HiSCR75 at Week 16, symptom diaries tracking worst skin pain, and safety monitoring through vital signs, laboratory tests, and electrocardiograms. The total study participation may extend through Week 92 for ongoing safety evaluations. Participants will also be monitored for adverse events throughout the study duration.

Age: 18Years - 79YearsAll GendersPhase 2
25 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating ARQ-234, a subcutaneous injectable solution, in a first-in-human, Phase 1, double-blind, randomized, placebo-controlled study. The study aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARQ-234 in both healthy volunteers and participants with moderate to severe atopic dermatitis AD. The research includes multiple parts with staggered starts to understand effects in different participant groups. The study consists of three parts Part A involves single ascending dose SAD cohorts with healthy volunteers and AD participants Part B includes multiple ascending dose MAD cohorts with AD participants and Part C is a proof-of-concept expansion in AD participants. Participants receive ARQ-234 or placebo via subcutaneous injection, with dosing and escalation schedules varying by cohort. Each part evaluates increasing doses to study safety and drug behavior. Participants will be involved in screening, dosing, and follow-up visits lasting up to 16 weeks for Part A and up to 30 weeks for Parts B and C. Assessments include adverse event monitoring, disease severity scoring using the Eczema Area and Severity Index EASI, body surface area affected, itch severity, SCORAD, POEM, and Investigators Global Assessment scores. Blood samples will be collected to study drug concentrations. Safety evaluations, questionnaires, and clinical exams will monitor participants throughout the study.

Age: 18Years - 65YearsAll GendersPhase 1
7 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness and long-term safety of PP405, a medicated topical gel, for treating Androgenetic Alopecia in adult males aged 18 to 55. This phase 23 randomized, double-blind study involves men who have experienced hair loss for at least six months and have specific severity scores on the Norwood-Hamilton scale. Participants are randomly assigned to receive either PP405 topical gel or a non-medicated vehicle gel applied to the scalp once daily for 24 weeks. After this initial period, those on PP405 continue the treatment while participants initially on the vehicle are re-randomized to either PP405 or vehicle for an additional 28 weeks, creating a total treatment duration of 52 weeks to assess both efficacy and safety over time. Throughout the study, participants will be regularly assessed for changes in hair count and scalp coverage using both clinical and participant evaluations at weeks 12 and 24. Safety monitoring continues during the extension phase up to week 52. The primary outcome focuses on the change in non-vellus target area hair count at week 24, with secondary measures including participant assessments of scalp coverage and hair count improvements at weeks 12 and 24.

Age: 18Years - 55YearsMALEPhase 2Phase 3
63 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of a reformulated Levulan Kerastick solution combined with photodynamic therapy PDT to treat actinic keratosis AK on the face or bald scalp. This Phase 3, randomized, multi-center, evaluator-blind, vehicle-controlled study focuses on adults with 4 to 8 mild to moderate AK lesions. The study aims to measure the complete clearance rate of these lesions at 12 weeks and also assesses other outcomes like partial clearance, lesion count changes, recurrence, cosmetic results, and patient satisfaction. Participants are assigned to one of four groups based on whether they receive the active drug or a vehicle solution and on two different incubation times before blue light application. Up to two PDT sessions may be given depending on lesion clearance. The active drug is a topical solution of aminolevulinic acid hydrochloride ALA HCl 20%, compared to a vehicle solution without the active ingredient. A blue light PDT device is used during the treatment. During the study, participants will have clinic visits to assess lesion clearance and safety through evaluations of skin reactions, vital signs, and lab tests. Researchers will track outcomes at weeks 4, 8, 12, 20, and 24, including lesion clearance rates, cosmetic response, and patient satisfaction. The total study duration extends through these follow-up assessments, with safety monitoring throughout and a final evaluation at week 24.

Age: 18Years - 85YearsAll GendersPhase 3
12 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness and safety of a new formulation of Levulan Kerastick combined with photodynamic therapy PDT to treat actinic keratosis AK on the upper arms. This Phase 3, randomized, multi-center, and evaluator-blind study compares this treatment to a vehicle control in adults with mild to moderate AK lesions. The goal is to see how well the treatment clears the lesions and to assess its safety. Participants will be randomly assigned to receive either the Levulan Kerastick solution or a vehicle solution applied to the skin, followed by an incubation period under occlusion and exposure to blue light using a specialized device. Up to two PDT sessions may be given depending on how well lesions clear. The study includes multiple time points for assessing lesion clearance, cosmetic outcomes, patient satisfaction, and recurrence rates. Throughout the study, participants will be monitored through visits where the skin lesions are evaluated, safety assessments are made including skin reactions and lab tests, and patient feedback is collected. The primary outcome focuses on the complete clearance rate of AK lesions at Week 12. Secondary outcomes involve lesion clearance at various weeks up to 24, cosmetic responses, and recurrence. The total study duration includes treatment and follow-up assessments extending to Week 24.

Age: 18Years - 85YearsAll GendersPhase 3
22 locations